StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) income statement

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.56−0.07 (-0.51%)

Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –

ADMA Biologics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
64.7%
Operating margin
43.8%
Net margin
33.0%
Return on equity, FY2025
35.6%

Financial strength

Current ratio
6.97
Debt to equity
0.48
Debt to assets
28.7%
Cash to current liabilities
179.5%

Valuation

P/E ratio
19.4
Price to sales
5.93
Price to book
7.44
Dividend yield
–

See a number that looks wrong?